Cantor Fitzgerald Cuts Earnings Estimates for uniQure

uniQure (NASDAQ:QURE) – Equities researchers at Cantor Fitzgerald decreased their FY2024 earnings per share (EPS) estimates for shares of uniQure in a report released on Wednesday, November 6th. Cantor Fitzgerald analyst K. Kluska now anticipates that the biotechnology company will post earnings per share of ($3.19) for the year, down from their previous estimate of ($3.14). Cantor Fitzgerald has a “Overweight” rating and a $28.00 price target on the stock. The consensus estimate for uniQure’s current full-year earnings is ($3.95) per share.

uniQure (NASDAQ:QURE) last posted its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, topping the consensus estimate of ($1.12) by $0.21. The firm had revenue of $2.29 million during the quarter, compared to the consensus estimate of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%.

Several other equities analysts have also recently weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $25.00 price target on shares of uniQure in a research report on Wednesday, November 6th. StockNews.com upgraded uniQure to a “sell” rating in a research report on Thursday, October 17th. The Goldman Sachs Group cut their price objective on shares of uniQure from $10.00 to $9.00 and set a “neutral” rating for the company in a research report on Wednesday, November 6th. Royal Bank of Canada reduced their price objective on shares of uniQure from $16.00 to $14.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. Finally, Raymond James reissued an “outperform” rating and issued a $20.00 price target on shares of uniQure in a report on Thursday, October 10th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $17.00.

uniQure Stock Down 1.7 %

uniQure stock opened at $7.66 on Monday. The firm has a 50 day simple moving average of $5.77 and a 200 day simple moving average of $5.84. The company has a current ratio of 6.51, a quick ratio of 7.36 and a debt-to-equity ratio of 0.92. uniQure has a 1-year low of $3.73 and a 1-year high of $11.35. The firm has a market capitalization of $373.35 million, a price-to-earnings ratio of -1.54 and a beta of 0.90.

Institutional Investors Weigh In On uniQure

A number of institutional investors and hedge funds have recently bought and sold shares of QURE. abrdn plc increased its holdings in shares of uniQure by 381.7% in the 3rd quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock worth $9,510,000 after buying an additional 1,528,581 shares during the last quarter. Acadian Asset Management LLC lifted its stake in uniQure by 133.1% during the first quarter. Acadian Asset Management LLC now owns 613,490 shares of the biotechnology company’s stock worth $3,189,000 after purchasing an additional 350,291 shares during the last quarter. Ikarian Capital LLC increased its position in shares of uniQure by 198.1% during the 1st quarter. Ikarian Capital LLC now owns 469,133 shares of the biotechnology company’s stock valued at $2,439,000 after purchasing an additional 311,768 shares during the last quarter. Assenagon Asset Management S.A. purchased a new position in shares of uniQure during the 2nd quarter valued at about $815,000. Finally, Vanguard Group Inc. lifted its position in uniQure by 11.4% in the 1st quarter. Vanguard Group Inc. now owns 1,072,536 shares of the biotechnology company’s stock worth $5,577,000 after buying an additional 109,740 shares during the last quarter. 78.83% of the stock is owned by hedge funds and other institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.